Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy
Armed Forces Hospital, Pakistan
200 participants
Jan 1, 2024
INTERVENTIONAL
Conditions
Summary
Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births. Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.
Eligibility
Inclusion Criteria2
- all indoor newborn babies with HIE II and III
- who have not received therapeutic hypothermia
Exclusion Criteria4
- grade I HIE
- Babies on TH
- babies whose parents do not give consent for inclusion in study
- babies with major congential malformations -
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06522581